Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Mario E. Lacouture, Brigitte Dréno, Paolo A. Ascierto, et al.
The Oncologist (2016) Vol. 21, Iss. 10, pp. 1218-1229
Open Access | Times Cited: 148

Showing 1-25 of 148 citing articles:

Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
Ketty Peris, Maria Concetta Fargnoli, Claus Garbe, et al.
European Journal of Cancer (2019) Vol. 118, pp. 10-34
Open Access | Times Cited: 509
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline
Célèste Lebbé, Jürgen C. Becker, Jean‐Jacques Grob, et al.
European Journal of Cancer (2015) Vol. 51, Iss. 16, pp. 2396-2403
Closed Access | Times Cited: 478
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulić, Michael R. Migden, Nicole Basset‐Séguin, et al.
BMC Cancer (2017) Vol. 17, Iss. 1
Open Access | Times Cited: 377
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
Nicole Basset‐Séguin, Axel Hauschild, Rainer Kunstfeld, et al.
European Journal of Cancer (2017) Vol. 86, pp. 334-348
Open Access | Times Cited: 258
Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology
Simone Garcovich, Giuseppe Colloca, Pietro Sollena, et al.
Aging and Disease (2017) Vol. 8, Iss. 5, pp. 643-643
Open Access | Times Cited: 194
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
Brigitte Dréno, Rainer Kunstfeld, Axel Hauschild, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 3, pp. 404-412
Closed Access | Times Cited: 184
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
Ketty Peris, Maria Concetta Fargnoli, Roland Kaufmann, et al.
European Journal of Cancer (2023) Vol. 192, pp. 113254-113254
Open Access | Times Cited: 121
Update in the Management of Basal Cell Carcinoma
Nicole Basset‐Séguin, F. Herms
Acta Dermato Venereologica (2020) Vol. 100, Iss. 11, pp. adv00140-adv00140
Open Access | Times Cited: 113
Hedgehog signaling inhibitors in solid and hematological cancers
Jorge E. Cortés, Ralf Gutzmer, Mark W. Kieran, et al.
Cancer Treatment Reviews (2019) Vol. 76, pp. 41-50
Open Access | Times Cited: 108
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Michael R. Savona, Daniel A. Pollyea, Wendy Stock, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 10, pp. 2294-2303
Open Access | Times Cited: 95
Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
Masaru Katoh
Clinical Science (2019) Vol. 133, Iss. 8, pp. 953-970
Closed Access | Times Cited: 90
Targeting cancer stem cells in drug discovery: Current state and future perspectives
Fangyu Du, Qifan Zhou, Wenjiao Sun, et al.
World Journal of Stem Cells (2019) Vol. 11, Iss. 7, pp. 398-420
Open Access | Times Cited: 89
Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer
Richard L. Carpenter, Haimanti Ray
Drug Safety (2019) Vol. 42, Iss. 2, pp. 263-279
Open Access | Times Cited: 86
Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis
Pingxing Xie, Philippe Lefrançois
Journal of the American Academy of Dermatology (2018) Vol. 79, Iss. 6, pp. 1089-1100.e17
Closed Access | Times Cited: 84
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study)
Nicolas Bertrand, P. Guerreschi, Nicole Basset‐Séguin, et al.
EClinicalMedicine (2021) Vol. 35, pp. 100844-100844
Open Access | Times Cited: 70
Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy
Alessandro Villa, Michal Kuten‐Shorrer
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8188-8188
Open Access | Times Cited: 22
Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas
Sachin Jain, Ruolan Song, Jingwu Xie
OncoTargets and Therapy (2017) Vol. Volume 10, pp. 1645-1653
Open Access | Times Cited: 85
Vismodegib: A Review in Advanced Basal Cell Carcinoma
James E. Frampton, Nicole Basset‐Séguin
Drugs (2018) Vol. 78, Iss. 11, pp. 1145-1156
Closed Access | Times Cited: 78
Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma
Ralf Gutzmer, James Solomon
Targeted Oncology (2019) Vol. 14, Iss. 3, pp. 253-267
Closed Access | Times Cited: 72
An evolving paradigm of cancer stem cell hierarchies: therapeutic implications
Alexander J. Cole, A Fayomi, Vivian I. Anyaeche, et al.
Theranostics (2020) Vol. 10, Iss. 7, pp. 3083-3098
Open Access | Times Cited: 52
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
Paolo Bossi, Paolo A. Ascierto, Nicole Basset‐Séguin, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 189, pp. 104066-104066
Open Access | Times Cited: 21
Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.
H. B. Singh, Hitesh Chopra, Inderbir Singh, et al.
PubMed (2024) Vol. 23, pp. 300-334
Closed Access | Times Cited: 6
Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib
Archana Kumari, Alexandre N. Ermilov, Marina Grachtchouk, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 48
Open Access | Times Cited: 54
Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma
Alessandro Villa, Gabriella Fabbrocini, Cláudia Costa, et al.
Dermatology and Therapy (2020) Vol. 10, Iss. 3, pp. 401-412
Open Access | Times Cited: 46
Known and new facts on basal cell carcinoma
Magdalena Seidl‐Philipp, Nina Frischhut, Nicole Höllweger, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 7, pp. 1021-1041
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top